GLA
NKTR icon

Great Lakes Advisors’s Nektar Therapeutics NKTR Stock Holding History

Great Lakes Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$269K Buy
+3,741
New +$213K ﹤0.01% 716
2025
Q4 		– Sell
-3,922
Closed -$223K – 835
2025
Q3 		$223K Buy
+3,922
New +$130K ﹤0.01% 758

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Lakes Advisors's NKTR Position: Q1 2026 in Review

Great Lakes Advisors opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 3,741 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #716 among its holdings. This is a return to the name: Great Lakes Advisors previously reported a position in NKTR as recently as Q3 2025.

Great Lakes Advisors first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Great Lakes Advisors held 3,741 shares of Nektar Therapeutics worth $269K as of Q1 2026.
  • Nektar Therapeutics was a new Great Lakes Advisors position in Q1 2026.
  • Nektar Therapeutics made up ﹤0.01% of Great Lakes Advisors's portfolio in Q1 2026, its #716 holding.
  • Great Lakes Advisors first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Great Lakes Advisors's 13F filing for Q1 2026, filed 12 May 2026.